PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease Reportsendometrial neoplasms
MeSH D016889 - endometrial neoplasms
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D014594:Uterine neoplasms
28 Companies
5 Drugs
$
Success rate
D016889: 
Endometrial neoplasms
57 Companies
12 Drugs
$
Success rate
D018269:Endometrioid carcinoma
0 Companies
0 Drugs
Success rate
D036821:Endometrial stromal tumors
0 Companies
0 Drugs
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaCarboplatin Carboplatin  2005-09-21   
Medroxyprogesterone Medroxyprogesterone  2004-10-27   
Megestrol Megestrol  1998-02-27   
Cyclophosphamide Neosar  1993-04-29   
Novast LaboratoriesCarboplatin Carboplatin  2017-04-26   
Dr Reddys LaboratoriesCyclophosphamide Cyclophosphamide 2036-02-15 2020-07-30   
MylanCarboplatin Carboplatin  2007-04-24   
NATCO PharmaCarboplatin Carboplatin  2012-05-29   
XiromedMedroxyprogesterone Medroxyprogesterone  2018-10-12   
Johnson & JohnsonLeuprolide Viadur  2000-03-03   
GSKDostarlimab Jemperli  2021-04-21   
CiplaCarboplatin Carboplatin  2006-01-27   
Cyclophosphamide Cyclophosphamide  2019-01-18   
Medroxyprogesterone Medroxyprogesterone  2019-01-25   
SandozCarboplatin Carboplatin  2005-03-18   
Leuprolide Leuprolide  1998-08-04   
Medroxyprogesterone Medroxyprogesterone  2009-05-20   
Cyclophosphamide Cyclophosphamide  2023-09-12   
1
2
3
4
5
6
>
Clinical Trials
Historical Success Rate
Phase 1
71%
77/108
Phase 2
24%
36/151
Phase 3
26%
14/53
Approved: 7Overall Success rate: 4%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Teva
Carboplatin,
Cyclophosphamide,
Medroxyprogesterone,
Medroxyprogesterone acetate
Mylan
Carboplatin
Johnson & Johnson
Leuprolide,
Leuprolide acetate
GSK
Dostarlimab,
Gilvetmab,
Bevifimod,
Doxecitine,
Nepidermin,
Globulin, immune,
Anthracycline,
Aminoglycoside,
Doxorubin,
Histone-arginine methyltransferase carm1,
Hydroxydaunomycin,
Surlorian,
Taxane
Sandoz
Carboplatin
AbbVie
Leuprolide,
Norethindrone,
Leuprolide acetate,
Budigalimab,
Globulin, immune,
IMGN151
Sanofi
Leuprolide,
Leuprolide acetate,
Levoglucose,
Nepidermin,
PILARALISIB,
SERIBANTUMAB,
Docetaxol,
Taxane
Merck & Co
Pembrolizumab,
Sacituzumab,
Chlormadinone acetate,
Gilvetmab,
Caficrestat,
Epacadostat,
Aglatimagene besadenovec,
Patritumab,
Ridaforolimus,
Patritumab deruxtecan,
Aspartame,
Bevifimod,
Doxecitine,
Favezelimab,
Nepidermin,
SECLIDEMSTAT,
Telbermin,
Vibostolimab,
Vilobelimab,
Globulin, immune,
Anthracycline,
Nerofe,
Aminoglycoside,
Doxorubin,
Mk3475,
Gestapuran,
NC-410,
NP137,
REZATAPOPT,
Histone-arginine methyltransferase carm1,
Gemcis,
Hydroxydaunomycin,
Olomorasib,
Surlorian,
Docetaxol,
Taxane,
Sacituzumab tirumotecan,
Depoprovera,
Sominex
Pfizer
Medroxyprogesterone,
Medroxyprogesterone acetate,
Giredestrant,
Tiragolumab,
Ipatasertib,
Sasanlimab,
Gilvetmab,
Spartalizumab,
Terfenadine,
Bevifimod,
Gedatolisib,
Globulin, immune,
Ag013736,
Lactams,
Pd0332991
1
2
3
4
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use